ARMATA PHARMACEUTICALS INC ARMP 深 滬
等待開盤 01-29 09:30:00 美东时间
6.46
-0.130
-1.97%
華盛通- 最 高6.64
- 今 開6.54
- 成交量 2.73万股
- 最 低 6.1364
- 昨 收 6.59
- 總市值 2.35亿
- 52周最高 16.34
- 市盈率 靜 --
- 換手率 0.08%
- 52周最低 0.8981
- 委 比 0.00%
- 總股本 3632.98万
- 歷史最高 16.34
- 量 比 0.84
- 振 幅 7.64%
- 歷史最低 0.8311
- 每 手 1
- 風險率 1.88%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅36.7%！LMRI获多家大行首予超配评级； 瑞银下调甲骨文目标价从325美元至280美元
今日重点评级关注：HC Wainwright & Co.：维持Assertio Holdings"买入"评级，目标价从3美元升至35美元；HC Wainwright & Co.：维持万达生物制药"买入"评级，目标价从20美元升至22美元
01-06 17:52
Jones Trading Initiates Coverage On Armata Pharmaceuticals with Buy Rating, Announces Price Target of $15
Jones Trading analyst Debanjana Chatterjee initiates coverage on Armata Pharmaceuticals (AMEX:ARMP) with a Buy rating and announces Price Target of $15.
01-06 00:37
Armata Pharmaceuticals Q3 EPS $(0.74) Misses $(0.42) Estimate, Sales $1.159M Miss $1.380M Estimate
Armata Pharmaceuticals (AMEX:ARMP) reported quarterly losses of $(0.74) per share which missed the analyst consensus estimate of $(0.42) by 76.19 percent. This is a 393.33 percent decrease over losses of $(0.15) per
2025-11-13 05:40
Armata Pharmaceuticals Commissions Good Manufacturing Practice Production Facility In Los Angeles
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the
2025-11-10 20:07
美股牛股 | ARMP大涨超103%！抗血感染药物在中期试验中显示出积极结果；直觉外科公司涨近14%
ARMP大涨超103%！抗血感染药物在中期试验中显示出积极结果；直觉外科公司涨近14%，Q3业绩表现优异，远超市场预期>>
2025-10-23 14:51
Here’s Why Armata Pharmaceuticals Stock (ARMP) Exploded 300% Today
Armata Pharmaceuticals ($ARMP) stock exploded nearly 300% on Wednesday after th...
2025-10-23 03:53
Armata Pharma Reports Results From Its Recently Completed Phase 2a diSArm Study Of AP-SA02 As A Potential Treatment For Complicated Staphylococcus Aureus Bacteremia In A Late-Breaking Oral Presentation At IDWeek 2025
Armata Pharmaceuticals, Inc. (NYSE:ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of
2025-10-22 23:12
Armata Pharmaceuticals Advances Cystic Fibrosis Infection Treatment With Phage Research
Armata Pharmaceuticals, Inc. (NYSE:ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of
2025-09-08 19:11
Armata Pharmaceuticals Announces Structural Biology Publication in the Journal of Molecular Biology
Describes the structure of phage Pa223, which is included in Armata's multi-phage anti-Pseudomonas clinical candidate, AP-PA02 LOS ANGELES, Sept. 8, 2025 /PRNewswire/ -- Armata Pharmaceutica...
2025-09-08 19:00
Armata Pharmaceuticals Q2 EPS $(0.45) Misses $(0.39) Estimate, Sales $2.169M Beat $1.380M Estimate
Armata Pharmaceuticals (AMEX:ARMP) reported quarterly losses of $(0.45) per share which missed the analyst consensus estimate of $(0.39) by 15.38 percent. This is a 80 percent decrease over losses of $(0.25) per share
2025-08-13 04:32
